Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A California federal district court denied Gilead Sciences, Inc. and Kite Pharma, Inc.’s motion to dismiss unpaid overtime claims under the Fair Labor Standards Act of two cell therapy specialists ...

Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to US$7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...

A new leadership team helmed by Johnson & Johnson alum Paul Stoffels was entrenching Galapagos into cell therapy, but Gilead already had this space covered with Kite Pharma, which it acquired in 2017 ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

As with all products, we will keep its safety under close review.” The approval comes just days after Gilead and LEO Pharma entered into a strategic partnership worth $1.7bn to advance LEO’s small ...

Financially robust, ACLX has cash reserves to fund operations into 2027, supported by a collaboration with Gilead's Kite subsidiary ... the same trajectory as a Kite Pharma.

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...